Vatalanib
Vatalanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against vascular endothelial growth factor receptor 2. In addition, it is known to target platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 3, and vascular endothelial growth factor receptor 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 7 | 2 | — | — | — | 8 | |
| Non-small-cell lung carcinoma | D002289 | 2 | 2 | — | — | — | 3 | ||
| Melanoma | D008545 | 2 | 2 | — | — | — | 3 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | 2 | 2 | — | — | — | 3 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
| Islet cell carcinoma | D018273 | C25.4 | 1 | 1 | — | — | — | 2 | |
| Neoplasm metastasis | D009362 | EFO_0009708 | 2 | 1 | — | — | — | 2 | |
| Prostatic neoplasms | D011471 | C61 | 1 | 2 | — | — | — | 2 | |
| Sarcoma | D012509 | — | 2 | — | — | — | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | 1 | — | — | — | — | 1 | ||
| Insulinoma | D007340 | 1 | — | — | — | — | 1 | ||
| Pheochromocytoma | D010673 | 1 | — | — | — | — | 1 | ||
| Neuroendocrine carcinoma | D018278 | 1 | — | — | — | — | 1 | ||
| Medullary carcinoma | D018276 | 1 | — | — | — | — | 1 | ||
| Gastrinoma | D015408 | 1 | — | — | — | — | 1 | ||
| Glucagonoma | D005935 | 1 | — | — | — | — | 1 | ||
| Somatostatinoma | D013005 | 1 | — | — | — | — | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VATALANIB |
| INN | vatalanib |
| Description | Vatalanib is a member of the class of phthalazines that is phthalazine in which the hydrogens at positions 1 and 4have been replaced by a p-chlorophenylamino group and a pyridin-4-ylmethyl group, respectively. It is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, an angiogenesis inhibitor and a vascular endothelial growth factor receptor antagonist. It is a member of phthalazines, a member of pyridines, a member of monochlorobenzenes and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 212141-54-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL101253 |
| ChEBI ID | 90620 |
| PubChem CID | 151194 |
| DrugBank | DB04879 |
| UNII ID | 5DX9U76296 (ChemIDplus, GSRS) |
Target
Agency Approved
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
PDGFRB
PDGFRB
FLT4
FLT4
FLT1
FLT1
Organism
Homo sapiens
Gene name
PDGFRB
Gene synonyms
PDGFR, PDGFR1
NCBI Gene ID
Protein name
platelet-derived growth factor receptor beta
Protein synonyms
Activated tyrosine kinase PDGFRB, Beta platelet-derived growth factor receptor, Beta-type platelet-derived growth factor receptor, CD140 antigen-like family member B, CD140b, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-1, PDGFR-beta, Platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Pdgfrb (18596)
platelet-derived growth factor receptor beta (P05622)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,058 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more